Provided by Tiger Trade Technology Pte. Ltd.

Omnicell

32.75
-2.4500-6.96%
Post-market: 32.750.00000.00%19:19 EDT
Volume:443.35K
Turnover:14.69M
Market Cap:1.49B
PE:725.16
High:34.72
Open:34.66
Low:32.69
Close:35.20
52wk High:55.00
52wk Low:22.66
Shares:45.44M
Float Shares:44.35M
Volume Ratio:0.80
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0452
EPS(LYR):0.0400
ROE:0.17%
ROA:0.36%
PB:1.21
PE(LYR):818.75

Loading ...

Omnicell EVP and Chief Legal/Admin Officer Corey J. Manley disposes of USD 257,006 of common shares

Reuters
·
Mar 18

Omnicell management to meet with Piper Sandler

TIPRANKS
·
Mar 12

Omnicell management to meet virtually with Benchmark

TIPRANKS
·
Mar 10

Omnicell FY 2025 effective tax rate hits 82% (USD 9.3 million income tax expense)

Reuters
·
Feb 27

Omnicell (OMCL) Gets a Buy from Piper Sandler

TIPRANKS
·
Feb 23

Omnicell EVP and Chief Legal/Admin Officer Corey J. Manley Disposes of Common Shares

Reuters
·
Feb 19

Does Omnicell’s Profit Squeeze Amid Higher Sales and 2026 Outlook Change The Bull Case For OMCL?

Simply Wall St.
·
Feb 16

Omnicell Earnings Call: Growth Intact, Margins Under Strain

TIPRANKS
·
Feb 07

Stock Track | Omnicell Plummets 5.21% Intraday After Piper Sandler Slashes Price Target

Stock Track
·
Feb 07

Omnicell Price Target Cut to $49.00/Share From $63.00 by Piper Sandler

Dow Jones
·
Feb 06

Omnicell: Solid Execution and Strategic Promise Offset by Near-Term Profitability Pressures and Premium Valuation (Hold Rating Maintained)

TIPRANKS
·
Feb 06

Stock Track | Omnicell Soars 14.84% After-Hours on Strong Revenue Guidance and Analyst Optimism

Stock Track
·
Feb 06

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Omnicell (OMCL) and MiMedx Group (MDXG)

TIPRANKS
·
Feb 05

Stock Track | Omnicell Plummets 14.99% Intraday After Q4 Earnings Miss and Weak 2026 Guidance

Stock Track
·
Feb 05

Stock Track | Omnicell Plunges 10.56% Pre-Market After Q4 Earnings Miss and Weak Guidance

Stock Track
·
Feb 05

Omnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Recurring Revenue Growth

Reuters
·
Feb 05

Omnicell sees FY26 adjusted EPS $1.65-$1.85, consensus $1.88

TIPRANKS
·
Feb 05

Omnicell Q4 EPS misses estimates

Reuters
·
Feb 05

Omnicell Inc. Q4 2025 GAAP net income drops to USD -2 million, reversing from previous profit

Reuters
·
Feb 05

Omnicell Q4 2025 Adj. EPS $0.40 Misses $0.50 Estimate, Sales $313.984M Beat $313.390M Estimate

Benzinga
·
Feb 05